Advertisement

Topics

Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 Pipeline Review, H1 2018 [Report Updated: 16052018] Prices from USD $3500

21:22 EDT 10 Aug 2018 | BioPortfolio Reports

Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 Pipeline Review, H1 2018


Summary


Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 Tyrosineprotein kinase receptor UFO is an enzyme encoded by the AXL gene. It plays a role in various processes such as endothelial cell survival during acidification by preventing apoptosis, optimal cytokine signaling during human natural killer cell development, hepatic regeneration, gonadotropinreleasing hormone neuron survival and migration, platelet activation, or regulation of thrombotic responses. It plays also an important role in inhibition of Tolllike receptors TLRsmediated innate immune response.


Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 pipeline Target constitutes close to 27 molecules. Out of which approximately 26 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in PreRegistration, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 4, 5, 1, 12 and 2 respectively.


Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular and Respiratory which include indications NonSmall Cell Lung Cancer, Acute Myelocytic Leukemia AML, Acute Myeloblastic Leukemia, Solid Tumor, Breast Cancer, Ovarian Cancer, Refractory Acute Myeloid Leukemia, Pancreatic Cancer, Relapsed Acute Myeloid Leukemia, Bladder Cancer, Chronic Lymphocytic Leukemia CLL, Chronic Myelocytic Leukemia CML, Chronic Myeloid Leukemia, Gastric Cancer, Hepatocellular Carcinoma, Lung Adenocarcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Renal Cell Carcinoma, Renal Cell Carcinoma, Soft Tissue Sarcoma, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Adrenocortical Carcinoma Adrenal Cortex Cancer, Bile Duct Cancer Cholangiocarcinoma, Bone Metastasis, Carcinoid Tumor, Colorectal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Esophageal Cancer, Ewing Sarcoma, Fallopian Tube Cancer, Gastrointestinal Stromal Tumor GIST, Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Idiopathic Pulmonary Fibrosis, Kidney Cancer Renal Cell Cancer, Liposarcoma, Liver Cancer, Lung Cancer, Merkel Cell Carcinoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Breast Cancer, Metastatic Melanoma, Metastatic Prostate Cancer, Myelodysplastic Syndrome, Neuroendocrine Gastroenteropancreatic Tumors GEPNET, Neuroendocrine Tumors, NonRhabdomyosarcoma, Ocular Melanoma, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Peritoneal Cancer, Pheochromocytoma, Recurrent Glioblastoma Multiforme GBM, Recurrent Head And Neck Cancer Squamous Cell Carcinoma, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Rhabdomyosarcoma, Thrombosis, Thyroid Cancer, Transitional Cell Carcinoma Urothelial Cell Carcinoma, Ureter Cancer, Urethral Cancer, Uterine Cancer and Wilms' Tumor Nephroblastoma.


The latest report Tyrosine Protein Kinase Receptor UFO Pipeline Review, H1 2018, outlays comprehensive information on the Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. It also reviews key players involved in Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics development with respective active and dormant or discontinued projects.


The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1

The report reviews Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics and enlists all their major and minor projects

The report assesses Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 Pipeline Review, H1 2018 [Report Updated: 16052018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Tyrosine Protein Kinase Receptor UFO AXL Oncogene or AXL or EC 2.7.10.1 Pipeline Review, H1 2018 [Report Updated: 16052018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...